The financials
Taysha Gene Therapies, Inc. by the numbers
Taysha Gene Therapies, Inc. (TSHA) reported revenue of $0 in Q1 2026 (quarter ended March 31, 2026), down 100% from the same quarter a year earlier. That came with net loss of $42M. For the full year FY2025, revenue was $9.8M (+17% year on year) and net income −$109M.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $2.3M | to a loss |
| Operating income | −$43M | −$21M | n/a |
| Net income | −$42M | −$22M | n/a |
| Diluted EPS | −$0.12 | −$0.08 | n/a |